KRAS and colorectal carcinoma: Interestingly, in a subsequent blood sample (CRC-0094) collected six months after the second collection, at a time the patient had to be switched to bevacizumab treatment, while the two original mutations were still undetectable, a new driver mutation was detected in the KRAS gene (G60D at 1.2%).